31 completed, 12 recruiting, 7 terminated, 6 active not recruiting. 30 Phase 2, 14 Phase 1, 11 Phase 3, 8 Phase 4, 5 Early Phase 1.
Follow Epidiolex: new trials by email Literature Review of Epidiolex trials Research Report on Epidiolex
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS Cannabidiol Oral Solution - Lennox-Gastaut Syndrome | Phase 4 | Not yet recruiting | Jazz Pharmaceuticals | 40 | 2026-11-18 | 2026-10-22 |
| Study of Cannabidiol in Sanfilippo Syndrome Epidiolex, Placebo - Sanfilippo Syndrome, Mucopolysaccharidosis III | Phase 2 / Phase 3 | Recruiting | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 35 | 2026-04-01 | 2026-09-15 |
| CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury CBD - Supra-sacral Spinal Cord Injury, Spinal Cord Injury | Phase 2 | Recruiting | University of Wisconsin, Madison | 20 | 2026-02-13 | 2026-09-16 |
| Study of Cannabidiol and Neuroimaging on Stress Cannabidiol, Placebo - Early Life Adversity, Trauma | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 160 | 2025-10-29 | 2026-09-10 |
| Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors Biospecimen Collection, Cannabidiol, Dronabinol - Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Recruiting | City of Hope Medical Center | 120 | 2025-10-03 | 2025-12-05 |
| Effects of Cannabidiol on Stress and Nicotine Withdrawal Epidiolex - CBD, Stress | Phase 1 | Recruiting | Johns Hopkins University | 90 | 2025-08-25 | 2026-08-10 |
| Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy Epidiolex - Maternal Complications, Pregnancy Complication | Recruiting | Jazz Pharmaceuticals | 50 | 2025-08-05 | 2026-10-02 | |
| Investigating the Effects of Cannabidiol on Social Anxiety Disorder Cannabidiol, Placebo - Phobia, Social | Phase 4 | Recruiting | Massachusetts Institute of Technology | 50 | 2025-07-10 | 2026-08-11 |
| Cannabidiol in Sickle Cell Disease Cannabidiol, Placebo - Sickle Cell Disease | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 52 | 2025-04-03 | 2025-06-25 |
| Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors Cannabidiol, Delta-8-Tetrahydrocannabinol, Placebo Administration - Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy | Early Phase 1 | Withdrawn | City of Hope Medical Center | 2024-07-06 | 2024-08-09 | |
| CBD for Pain Following Orthopedic Shoulder Surgery Epidiolex, Placebo oral solution - Shoulder Osteoarthritis, Rotator Cuff Injuries | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 80 | 2024-05-24 | 2026-04-16 |
| MIVetsCan: Cannabidiol (CBD)-Care Trial Placebo, Cannabidiol - Pain, Chronic | Phase 2 | Recruiting | Kevin Boehnke | 468 | 2024-02-12 | 2026-06-01 |
| Clinical Study to Evaluate Cannabidiol Liver Enzyme Elevations and Drug Interactions Cannabidiol, Placebo, Citalopram - Cannabidiol, Drug Induced Liver Injury | Phase 1 | Completed | Food and Drug Administration (FDA) | 241 | 2024-02-08 | 2025-07-31 |
| Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis IHL-675A, Cannabidiol, Hydroxychloroquine - Rheumatoid Arthritis | Phase 2 | Terminated | Incannex Healthcare Ltd | 20 | 2023-11-22 | 2026-03-27 |
| A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex Cannabidiol Oral Solution [Epidiolex] - Tuberous Sclerosis Complex Associated Neuropsychiatric Disease | Phase 4 | Completed | Jazz Pharmaceuticals | 79 | 2023-06-29 | 2026-04-27 |
| Cannabidiol to Reduce Anxiety Reactivity Cannabidiol, Placebo - Social Anxiety, Social Anxiety Disorder | Phase 2 | Completed | University of California, San Diego | 63 | 2023-04-19 | 2025-01-08 |
| Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting Epidiolex - Seizures | Active not recruiting | Jazz Pharmaceuticals | 158 | 2023-04-17 | 2026-06-15 | |
| Cannabidiol for Bilateral Total Knee Arthroplasty cannabidiol, Ora-sweet SF - Pain, Postoperative, Opioid Use | Phase 4 | Completed | Hospital for Special Surgery, New York | 37 | 2022-11-02 | 2026-05-26 |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures GWP42003-P, Placebo - Seizures Associated With EMAS | Phase 3 | Terminated | Jazz Pharmaceuticals | 3 | 2022-10-31 | 2025-02-03 |
| Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy Cannabidiol, Placebo Administration, Quality-of-Life Assessment - Chemotherapy-Induced Peripheral Neuropathy, Malignant Solid Neoplasm | Phase 2 | Completed | Mayo Clinic | 40 | 2022-06-09 | 2026-01-16 |
Showing 20 of 65. Sign in to see all of them.
Epilepsy (17) · Epilepsies, Myoclonic (6) · Lennox Gastaut Syndrome (6) · Opioid-Related Disorders (6) · Seizures (6) · Chronic Pain (4) · Anxiety Disorders (3) · Breast Neoplasms (3) · Pain (3) · Tuberous Sclerosis (3) · Arthralgia (2) · Colonic Neoplasms (2) · Drug Resistant Epilepsy (2) · Marijuana Abuse (2) · Osteoarthritis, Knee (2)
Jazz Pharmaceuticals (19) · University of California, San Diego (4) · Icahn School of Medicine at Mount Sinai (3) · Anne Comi, MD (2) · City of Hope Medical Center (2) · Johns Hopkins University (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · University of Alabama at Birmingham (2) · Yale University (2) · Yasmin Hurd (2) · Augusta University (1) · Brigham and Women's Hospital (1) · Dana-Farber Cancer Institute (1) · Eric Marsh, MD (1)
United States (55) · Spain (9) · United Kingdom (8) · Italy (5) · Netherlands (4) · Poland (4) · Australia (3) · France (3) · Canada (2) · Sweden (2) · Denmark (1) · Germany (1) · Israel (1)
Anne M Comi, MD (2) · Joao De Aquino, M.D. (2) · Yasmin Hurd, PhD (2) · Alexandra Sideris, PhD (1) · Amr Ahmed (1) · Casey Straud, PsyD (1) · Cecilia L Bergeria, PhD (1) · Charles Taylor, PhD (1) · Deepak Madhavan, MD (1) · Doris Trauner, MD (1) · Dustin C. Lee, PhD (1) · Guido K Frank, MD (1) · Ilana Braun, MD (1) · Javi Santiago (1) · Jay Salpekar (1)
PMID 29063814, PMID 31048098, PMID 33797076, PMID 33825230, PMID 34265088, PMID 37052803, PMID 40775196, PMID 29768152, PMID 30955420, PMID 32119035, PMID 32350749, PMID 32652616, PMID 34391393, PMID 36105269, PMID 36123113, PMID 38951902, PMID 39016024, PMID 39680411, PMID 40410546, PMID 40622698, PMID 40751295, PMID 41906184, PMID 42113179, PMID 42435131
2014 (7), 2015 (2), 2018 (2), P30CA033572 (2), 2019 (1), 2023 (1), K01DA049219 (1), K23DA052682 (1), KL2TR002646 (1), R01AT010381 (1), R01DA027232 (1), R01DA043535 (1), R01MH139940 (1), R21CA260447 (1), UL1TR002645 (1)